Recombinant Human BCMA/TNFRSF17 Protein, Atto 647N Conjugate SummaryLearn more about FluorokinesTM Fluorescent-Labeled Proteins
Accession # Q6PE46
|Formulation||Supplied as a 0.2 μm filtered solution in PBS with BSA as a carrier protein.|
|Shipping||The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Protect from light. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Fluorescent beads conjugated to anti-Human BCMA Monoclonal Antibody were stained with (A) Recombinant Human BCMA/TNFRSF17 Fc Chimera Atto 647N Protein (Catalog # ATM193) or (B) unstained.
2 μg/lane of Recombinant BCMA/TNFRSF17 Fc Chimera Atto 647N (ATM193) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 35-45 kDa and 70-90 kDa, respectively.
BCMA, B cell maturation antigen, also known as Tumor Necrosis Factor Receptor Superfamily member 17 (gene name TNSFR17), is a member of the TNFR superfamily, due to the presence of its TNFR motif (1). BCMA is a type III membrane protein containing one extracellular cysteine rich domain, a transmembrane domain, and an intracellular domain. Within the TNFRSF, it shares the highest homology with TACI. BCMA and TACI have both been shown to bind to APRIL and BAFF, members of the TNF ligand superfamily (2, 3). This binding to APRIL and BAFF has been shown to stimulate IgM production in peripheral B cells and increase the survival of cultured B cells (3, 4). This data suggests that BCMA may play an important role in B cell development, function, and regulation (5). BCMA expression has been found in immune organs and mature B cell lines (5). Although some expression has been observed at the cell surface, BCMA appears to be localized to the Golgi compartment (6). Within the ECD, human and mouse BCMA shares 62% amino acid identity. The expression of BCMA has also been linked to various cancers, autoimmune disorders, and infectious diseases (7). Proteolytic shedding of the BCMA extracellular domain generats soluble BCMA (sBCMA) via direct cleavage by gamma -secretase, and elevated sBCMA levels in serum may correlate with disease activity (8). More recently, BCMA has been indicated as a possible biomarker in various human immunological disease, and as a potential therapeutic target for multiple myeloma (MM) (9-11).
- Hatzoglou, A. et al. (2000). J Immunol. 165:1322.
- Schiemann, B. et al. (2001). Science. 293:2111.
- Marsters, S.A. et al. (2000) Curr. Biol. 10:785.
- Huang, H. et al. (2013). PNAS. 110:10928.
- Laâbi, Y. et al. (1994). Nucleic Acids Res. 22:1147.
- Gras, M. et al. (1995) Int. Immunol. 7:1093.
- Coquery, C.M. et al. (2012) Crit Rev Immunol. 32:287.
- Laurent, S.A. et al. (2015) Nat Commun. 6:7333.
- Thaler, F.S. et al. (2017) Neuro Oncol. 19:1618.
- Seckinger, A. et al. (2017) Cancer Cell. 31:396.
- Lee, L. et al. (2018) Blood. 131:746.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human BCMA/TNFRSF17 Protein, Atto 647N Conjugate
There are currently no reviews for this product. Be the first to review Recombinant Human BCMA/TNFRSF17 Protein, Atto 647N Conjugate and earn rewards!
Have you used Recombinant Human BCMA/TNFRSF17 Protein, Atto 647N Conjugate?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image